Gynalven

Gynalven is a prescription medication that contains micronised progesterone as its active ingredient. It is supplied as oral tablets, with the micronisation process enhancing absorption. The product is marketed in the European Union and is classified as a progestogen used in hormone replacement therapy. Gynalven does not have a listed strength in the provided data, but it follows standard dosing conventions for progesterone tablets generally commonly.

Gynalven is indicated for several hormonal and reproductive conditions where supplemental progesterone is required.

- Luteal phase support in assisted reproductive technologies such as in‑vitro fertilisation. - Hormone replacement therapy to alleviate menopausal symptoms associated with low progesterone. - Management of menstrual disorders, including amenorrhea and dysfunctional uterine bleeding. - Prevention of preterm birth in selected high‑risk pregnancies. - Adjunct therapy for certain cases of recurrent miscarriage linked to luteal insufficiency. - Support of endometrial preparation for embryo implantation in fertility treatments.

Side effects reported with micronised progesterone tablets vary in frequency and severity; most are mild and transient, while a few may require medical attention.

Common: - Mild headache or dizziness. - Nausea, abdominal discomfort or bloating. - Breast tenderness or swelling. - Fatigue or drowsiness. - Mood changes or irritability. - Weight gain or fluid retention. - Changes in libido.

Serious: - Allergic reactions such as rash, itching, or swelling of the face. - Signs of thromboembolic events, including sudden leg pain or shortness of breath. - Severe abdominal pain indicating possible liver dysfunction. - Unexplained vaginal bleeding. - Elevated liver enzymes indicating hepatic stress.

When prescribing Gynalven, clinicians consider several precautionary measures to ensure safe use and to minimise risk.

- Assess for a history of thromboembolic disease before initiating therapy. - Monitor liver function tests periodically during long‑term treatment. - Use caution in patients with uncontrolled hypertension or cardiovascular disease. - Evaluate for breast or uterine cancer, as progesterone may influence tumor growth. - Discuss potential mood changes with patients who have a history of depression. - Avoid use during known or suspected pregnancy unless specifically indicated.

Progesterone can interact with other medications by affecting metabolism or hormonal balance, so careful review of a patient’s drug regimen is recommended.

Avoid: - Concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) that may reduce progesterone levels. - Combined hormonal contraceptives containing estrogen, which can increase the risk of thromboembolic events.

Use with caution: - Antifungal agents such as ketoconazole that inhibit CYP3A4 and may raise progesterone concentrations. - Anticoagulants, because progesterone may potentiate their effect on bleeding time. - Sedatives or CNS depressants, as progesterone can enhance drowsiness.